newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

-- Study results comparing the anti-inflammatory effects of MYMD-1® to Enbrel (etanercept) accepted for poster presentation -- MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical